Literature DB >> 17190958

Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.

A A Argyriou1, E Chroni, P Polychronopoulos, G Iconomou, A Koutras, T Makatsoris, M K Gerolymos, P Gourzis, K Assimakopoulos, H P Kalofonos.   

Abstract

We conducted a randomized, open-label, controlled trial to assess the efficacy of oxcarbazepine for prophylaxis against oxaliplatin-induced peripheral neuropathy (OxIN). Thirty-two patients with colon cancer received 12 courses of the FOLFOX-4 regimen and were randomly assigned to receive oxcarbazepine (600 mg BID) or chemotherapy without oxcarbazepine. The incidence of OxIN was strikingly decreased in patients receiving oxcarbazepine (31.2% vs 75%). Oxcarbazepine may prevent OxIN symptoms. Further larger placebo-controlled trials are warranted to confirm our results.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17190958     DOI： 10.1212/01.wnl.0000249344.99671.d4

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  23 in total

Review 1.  Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.

Authors:  Marco Sisignano; Ralf Baron; Klaus Scholich; Gerd Geisslinger
Journal:  Nat Rev Neurol       Date:  2014-11-04       Impact factor: 42.937

Review 2.  Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies.

Authors:  Gerardo Gutiérrez-Gutiérrez; María Sereno; Ambrosio Miralles; Enrique Casado-Sáenz; Eduardo Gutiérrez-Rivas
Journal:  Clin Transl Oncol       Date:  2010-02       Impact factor: 3.405

Review 3.  Psychopharmacology in cancer.

Authors:  Seema M Thekdi; Antolin Trinidad; Andrew Roth
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

Review 4.  Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.

Authors:  Sang Hui Chu; Young Joo Lee; Eon Sook Lee; Yimin Geng; Xin Shelley Wang; Charles S Cleeland
Journal:  Support Care Cancer       Date:  2014-09-26       Impact factor: 3.603

Review 5.  Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source.

Authors:  Jiacheng Ma; Annemieke Kavelaars; Patrick M Dougherty; Cobi J Heijnen
Journal:  Cancer       Date:  2018-02-20       Impact factor: 6.860

6.  Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.

Authors:  Kathleen A Griffith; Shijun Zhu; Meg Johantgen; Michael D Kessler; Cynthia Renn; Andreas S Beutler; Rahul Kanwar; Nicholas Ambulos; Guido Cavaletti; Jordi Bruna; Chiara Briani; Andreas A Argyriou; Haralabos P Kalofonos; Laura M Yerges-Armstrong; Susan G Dorsey
Journal:  J Pain Symptom Manage       Date:  2017-07-23       Impact factor: 3.612

Review 7.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Authors:  Wolfgang Grisold; Guido Cavaletti; Anthony J Windebank
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 8.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

Authors:  Abolfazl Avan; Tjeerd J Postma; Cecilia Ceresa; Amir Avan; Guido Cavaletti; Elisa Giovannetti; Godefridus J Peters
Journal:  Oncologist       Date:  2015-03-12

Review 9.  Neurological adverse effects caused by cytotoxic and targeted therapies.

Authors:  David Schiff; Patrick Y Wen; Martin J van den Bent
Journal:  Nat Rev Clin Oncol       Date:  2009-08-25       Impact factor: 66.675

Review 10.  The challenges of colorectal cancer survivorship.

Authors:  Crystal S Denlinger; Andrea M Barsevick
Journal:  J Natl Compr Canc Netw       Date:  2009-09       Impact factor: 11.908
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.